Small-volume ELISA Recent launch of an ELISA platform designed for small sample volumes suggests a strong cross-sell opportunity to customers who require rapid, low-volume assays across proteomics, immunoassays, and personalized diagnostics.

Early-stage traction Funding history shows a $7M Series A and existing revenue in the low- to mid-range; target customers in academia and biotechs likely to adopt innovative microscale tools, indicating a receptive early adopter market for the PIXI platform.

Innovative PIXI platform PIX I platform enables dynamic monitoring from less than two microliters, highlighting opportunities to partner with instrument vendors and contract research organizations that need fast, scalable biomolecular interaction measurements.

Berkeley biotech hub Based in Berkeley with notable investor interest, leverage regional academia and startups for pilot programs, technology partnerships, and grant-backed collaborations that can accelerate adoption.

Competitive positioning Compared to established players with large scale revenues, Correlia’s focus on microscale, rapid measurements positions it to target boutique labs and niche biotechs seeking flexible, low-volume analytical solutions; articulate value against high-volume incumbents for acquisitions or collaborations.